Search Results

You are looking at 31 - 40 of 1,331 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Ali Mokdad, Travis Browning, John C. Mansour, Hao Zhu, Amit G. Singal, and Adam C. Yopp

on characteristic radiographic imaging on dynamic contrasted-enhanced CT or MRI. Most of these diagnostic imaging studies are ordered by primary care physicians, who are at the beginning of the cancer care continuum and must not only discern an

Full access

Dingcheng Shen, Xiaolin Wang, Heng Wang, Gaopo Xu, Yumo Xie, Zhuokai Zhuang, Ziying Huang, Juan Li, Jinxin Lin, Puning Wang, Meijin Huang, Yanxin Luo, and Huichuan Yu

Cancer Staging Manual 26 based on pelvic MRI and CT imaging. Figure 1. (A) Patient flow and (B) the timeline for the longitudinal analysis in this study. Patients were grouped based on CEA level and recurrent status. The clinical characteristics

Full access

Rebecca A. Vanderwall, Alison Schwartz, Lindsay Kipnis, Catherine M. Skefos, Samantha M. Stokes, Nizar Bhulani, Michelle Weitz, Rebecca Gelman, Judy E. Garber, and Huma Q. Rana

changes in demographic information, clinical history, meeting NCCN GT criteria, and family structure. Post-GC pedigrees were used to gather family characteristics, including cancer burden (reported as cancer ratio). Pedigrees that were left blank before

Full access

Andrew D. Zelenetz

highlighted the second-generation BCL-2 inhibitor venetoclax (ABT-199). Early studies with venetoclax have confirmed its activity and the durability of Figure 2 Ideal Characteristics of Immunoconjugates. responses in patients with relapsed

Full access

Yujiao Sun, Adam Hendrix, Benyam Muluneh, and Sachiko Ozawa

imatinib in the United States. Screenshots of included web pages were taken when pages were accessed. Information collected from these websites included patient safety characteristics, marketing techniques, and pricing information. Patient safety

Full access

Catherine Lockhart, Cara McDermott, James Marshall, Aaron Mendelsohn, Pamala Pawloski, and Jeffrey Brown

. Objective: To evaluate patient characteristics and treatment use patterns in patients treated with GCSFs. This analysis will help inform a large-scale, real-world, observational GCSF comparative effectiveness research (CER) study using the Biologics

Full access

Xiaoqin Yang, Kaushal Desai, Neha Agrawal, Kirti Mirchandani, Sagnik Chatterjee, Eric Sarpong, and Shuvayu Sen

describe the characteristics, treatment patterns, healthcare resource use (HRU) and costs for these patients. ​ Methods: A retrospective study of individuals enrolled in the MarketScan ® Commercial Claims and Encounters claims database from 10

Full access

Daniëlle D. Huijts, Julia T. van Groningen, Onno R. Guicherit, Jan Willem T. Dekker, Leti van Bodegom-Vos, Esther Bastiaannet, Johannes A. Govaert, Michel W. Wouters, and Perla J. Marang-van de Mheen

studies grouped colon and rectal surgeries together 3 , 4 or only examined colon surgery, 5 , 6 whereas patient characteristics, complication risks, and clinical outcomes are clearly different for colon and rectal cancers. 9 Another important

Full access

Sumesh Kachroo, Changxia Shao, Kaushal Desai, Jinghua He, Fan Jin, and Shuvayu Sen

Background: This study evaluated the relationship between patients’ clinical and genomic characteristics and high tumor mutational burden (TMB) in the context of small cell lung cancer (SCLC). Methods: This was a retrospective cohort study using

Full access

Héctor G. van den Boorn, Ameen Abu-Hanna, Nadia Haj Mohammad, Maarten C.C.M. Hulshof, Suzanne S. Gisbertz, Bastiaan R. Klarenbeek, Marije Slingerland, Laurens V. Beerepoot, Tom Rozema, Mirjam A.G. Sprangers, Rob H.A. Verhoeven, Martijn G.H. van Oijen, Koos H. Zwinderman, and Hanneke W.M. van Laarhoven

options. Furthermore, prediction models for the metastatic setting are scarce. We recently developed 2 models to predict survival in patients with metastatic esophageal or gastric cancer based on tumor, patient, and treatment characteristics. 13